Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
about
The fate of chemoresistance in triple negative breast cancer (TNBC)Antimitotic drugs in the treatment of cancerMicrotubule-stabilizing agents as potential therapeutics for neurodegenerative diseaseDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targetsRHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activityDiscovery and development of natural product oridonin-inspired anticancer agentsDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes.Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institutionHow transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after studyEpothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepiloneThe characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathiesIn vivo MRI of early stage mammary cancers and the normal mouse mammary glandDesign and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs.Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centresThe role of individual caspases in cell death induction by taxanes in breast cancer cells.Adjuvant Systemic Therapy of Breast Cancer.Fertility preservation and breast cancer: a reviewBreast cancer medications and vision: effects of treatments for early-stage disease.The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialTLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialEvaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Breast cancer and fertility preservationEfficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxelMacromolecules as taxane delivery systems.Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.Challenges in the management of breast cancer in low- and middle-income countries.The cancer biology of whole-chromosome instability.A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging.
P2860
Q26775232-770A0211-3C7C-45D4-82FC-C71BF6198368Q26777317-FC895BFE-84C1-45AF-8FC2-2A2D1D2C3E43Q26865234-4B713417-4889-49FB-BD0A-A8C4A7FFA002Q26865654-EA08A73E-FAF2-4C12-87BD-CDEE171802F6Q28285641-F97C2345-F12F-4BE9-8200-A3BD07FCB4DAQ28387804-355CA81B-5170-4CF0-B80F-04F333B01261Q28728830-9C81D9B2-7709-41D8-B85E-1A0B18FAFF0CQ30318240-63A9B6EA-B101-4859-B05D-C1E434FF8112Q30318419-5880DC7D-06EE-4473-82F5-6A1B4F3021E0Q30692336-8C699DDF-189C-4B7A-B114-9697DC275C68Q31024172-8BA76BA4-B93B-4FE1-93CB-C10EAAA01E72Q33710117-535115EE-470F-4261-8049-7EB2AC8EFBA3Q33972876-184FEAE0-3346-4A86-96BE-CC91F3DDC688Q34000716-85B08E89-C5C0-46E7-A533-DDF42F9682ECQ34218584-D505A929-B2CB-4D90-B3A3-B506FF5746F8Q34274930-208E5C15-97AC-42DC-B39B-405C89CA920AQ34587678-E6EBB46A-7DA4-40A3-8ABC-9C1D289AC813Q34610711-F3D2861E-A4EC-4164-93EE-D26BA50FE88DQ34987894-B0753200-03E5-46A5-A791-7DB57670F409Q35026994-C54D273F-CC88-4C38-B1C7-9C3FCF3B209BQ35085574-FECB9BEE-BD52-41EC-ACAB-D3711FEE3159Q35095595-04CC37F5-2C4C-42D2-9FC4-ECC81E49E651Q35106163-29B771D8-6A4B-4B09-99A0-43C59EA9B3ECQ35496778-78BBAA7C-669F-4B77-AE12-18914CAD8B7AQ35875920-9939C6D7-1F33-4E71-9504-708FDBE1871CQ35889568-E9B75C5C-E123-4EF7-B0A5-5FAE0801860FQ36027073-BA125847-6EF9-4DCF-BB18-EB8BDED7D421Q36102798-83FCE953-4C8C-4DA2-BC6F-06EB420B9752Q36278585-7DDCE8FE-F2DB-40FF-871C-685B685D34B3Q37356090-0BE87BDC-9FF1-4353-BAB9-86484555DEC2Q37612074-96FF9676-C96F-4C72-BC8E-CC14AC5A7F14Q37671839-9185D7C9-FDC2-4D7B-BE19-81FC0545ABCDQ37818236-BD4D0E3B-9F6C-4D87-BF08-75113A55812BQ38047388-C12B031D-291C-4C91-A8CC-59E57D81D56EQ38059133-AFD1F25A-33A7-46DD-A247-ACB4C1B85B7CQ38066589-C784CE99-53E1-4FD1-8B57-0F2D2DD670C7Q38074016-31DEEB62-D15B-4471-88D3-6DF538C63034Q38433690-C750CAFC-5C92-457A-B373-54DB76A7D90EQ39052949-4269B81E-E3C2-447A-BA44-923B6552CA88Q39237850-8932261B-CD84-4FBE-A8F9-C8FAA39BCFAD
P2860
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@en
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@nl
type
label
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@en
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@nl
prefLabel
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@en
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@nl
P50
P1476
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
@en
P356
10.1038/NRCLINONC.2009.186
P407
P577
2009-12-08T00:00:00Z